Global Uveitis market Research Report – Pipeline Review, H2 2017

“The Latest Research Report Uveitis-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. –”

About Uveitis Market

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Uveitis-Pipeline Review, H2 2017, provides an overview of the Uveitis (Ophthalmology) pipeline landscape.

Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication.

Request For Sample Report @

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Uveitis-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 5, 8, 5, 2, 25, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

View Sample PDF @


– The pipeline guide provides a snapshot of the global therapeutic landscape of Uveitis (Ophthalmology).

– The pipeline guide reviews pipeline therapeutics for Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Uveitis (Ophthalmology)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Uveitis (Ophthalmology).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Have Any Query? Ask Our Expert @

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Uveitis-Overview 8

Uveitis-Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 14

Products under Development by Companies 15

Products under Development by Universities/Institutes 19

Uveitis-Therapeutics Assessment 20

Assessment by Target 20

Assessment by Mechanism of Action 23

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Uveitis-Companies Involved in Therapeutics Development 30

2-BBB Medicines BV 30

AbbVie Inc 30

Aciont Inc 31

Alcon Laboratories Inc 31

Aldeyra Therapeutics Inc 31

Apitope International NV 32

Bionomics Ltd 32

Bristol-Myers Squibb Co 33

Can-Fite BioPharma Ltd 33

Clearside BioMedical Inc 34

Coherus BioSciences Inc 34

Elasmogen Ltd 35

Endocyte Inc 35

Enzo Biochem Inc 35

EyeGate Pharmaceuticals Inc 36

Eyevensys SAS 36

F. Hoffmann-La Roche Ltd 37

Galapagos NV 37

HanAll Biopharma Co Ltd 38

Icon Bioscience Inc 38

Idera Pharmaceuticals Inc 38

Johnson & Johnson 39

KPI Therapeutics Inc 39

Midatech Pharma Plc 40

Mitotech SA 40

Nemus Bioscience Inc 41

Novartis AG 41

Oculis ehf 42

OncoNOx ApS 42

Ophthotech Corp 42

Orchid Pharma Ltd 43

Palatin Technologies Inc 43

Panoptes Pharma GesmbH 44

pSivida Corp 44

Re-Pharm Ltd 45

Santen Pharmaceutical Co Ltd 45

SynDevRx Inc 45

TxCell SA 46

Uveitis-Drug Profiles 47

2B-3201-Drug Profile 47

abatacept-Drug Profile 49

adalimumab-Drug Profile 58

adalimumab biosimilar-Drug Profile 67

adalimumab biosimilar-Drug Profile 70

adalimumab biosimilar-Drug Profile 73

adalimumab biosimilar-Drug Profile 74

ADX-102-Drug Profile 75

About us is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074



Designed by
Powered by
%d bloggers like this: